Among the clinical features that we consider in comparison with PD1+ EVs levels, we chose LDH, which is a tumour marker accepted as a validated prognostic and predictive factor in MM patients, the BRAF status, the gender, the number of metastatic sites and the pre-treatment of patients with targeted therapy. Here, PDCD1 is linked to neoplasm.